MARSHALL WACE, LLP - RUBIUS THERAPEUTICS INC ownership

RUBIUS THERAPEUTICS INC's ticker is RUBY and the CUSIP is 78116T103. A total of 68 filers reported holding RUBIUS THERAPEUTICS INC in Q1 2019. The put-call ratio across all filers is - and the average weighting 1.2%.

Quarter-by-quarter ownership
MARSHALL WACE, LLP ownership history of RUBIUS THERAPEUTICS INC
ValueSharesWeighting
Q3 2022$184,000
-49.2%
425,4970.0%0.00%
-100.0%
Q2 2022$362,000
-85.4%
425,497
-5.8%
0.00%
-80.0%
Q1 2022$2,487,000
+2140.5%
451,505
+3765.3%
0.01%
+400.0%
Q4 2019$111,000
-96.1%
11,681
-92.7%
0.00%
-92.9%
Q1 2019$2,878,000159,0460.01%
Other shareholders
RUBIUS THERAPEUTICS INC shareholders Q1 2019
NameSharesValueWeighting ↓
ARCH Venture Management, LLC 2,618,351$41,187,00042.64%
Flagship Pioneering Inc. 38,296,526$602,404,00026.08%
HARBOURVEST PARTNERS LLC 1,973,756$31,048,0005.81%
Artal Group S.A. 2,833,791$44,576,0001.80%
EcoR1 Capital, LLC 463,152$7,285,0000.74%
Cormorant Asset Management, LP 600,000$9,438,0000.54%
Nikko Asset Management Americas, Inc. 1,254,158$19,728,0000.39%
Leap Investments LP 14,100$222,0000.30%
ARK Investment Management 698,402$10,986,0000.28%
Baillie Gifford 4,234,682$66,612,0000.07%
View complete list of RUBIUS THERAPEUTICS INC shareholders